IntroductIon
Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease of the central nervous system causing demyelination and axonal loss with associated neurological disability. It affects approximately 100 000 people in the UK, where it is the most common cause of acquired neurological disability in young adults. 1 Although disease-modifying treatments are available for patients with relapsing-remitting MS, treatment options for those with progressive disease are largely restricted to symptomatic therapies. Given the inadequacy of current treatment options, it is not surprising that patients with MS may seek experimental therapies and, if they cannot participate in regulated clinical trials or if they have firmly held views on the efficacy of a particular approach, they may explore alternative options.
Direct-to-consumer advertising of unproven interventions and accessibility of information via the internet have increased patient demand but there are increasing concerns, particularly with respect to clinical and financial risks presented to patients (not to mention the reputation of stem cell research). 2 3 To date, efforts to regulate this global problem have had little success 4 and, whilst patient autonomy must be respected, clinicians also have a responsibility to discuss potential risks and to advise patients against interventions considered inappropriate, unproven and potentially harmful. However, while neurologists may understand the level of evidence for stem cell therapy, they may be less familiar with the procedures and risks associated with transplantation, and with internationally agreed standards for transplant centres. Our aim is to provide practising neurologists with an overview of the autologous haematopoietic stem cell transplantation (AHSCT) process and a framework to assist when counselling patients considering stem cell 'tourism'. stem cell therApy for ms: whAt Is the AttrActIon? In AHSCT, haematopoietic stem cells rescue patients from fatal bone marrow failure (aplasia) induced by myeloablative chemotherapy or radiotherapy. In the context of MS, the rationale for this type of stem cell treatment is to permit exposure to powerful immunoablative therapies, 're-setting' the immune system. However, stem cell therapy has long been a promising treatment for a wide range of conditions for which current treatments are suboptimal or non-existent. The intuitive appeal of a ready source of cells that can multiply, migrate and differentiate to repair damaged tissues has led to considerable hype and expectation 5 although, to date, stem cell therapy including AHSCT is integral to treatment of relatively few How to do it figure 1 AHSCT schematic illustrating stages of AHSCT including mobilisation, collection, conditioning, storage and infusion. AHSCT, autologous haematopoietic stem cell transplantation; G-CSF,granulocyte-colony stimulating factor; HSC, haematopoietic stem cell; SCF, stem cell factor.
conditions outside haematology and oncology. More recently, the focus of research attention has shifted from the 'pluripotency' of stem cells to the potential benefit of harnessing non-canonical reparative properties including anti-inflammatory or immunomodulatory effects, neuroglial protective properties or angiogenesis. A range of mechanisms may effect these functions via paracrine activity and cell fusion. 6 Neurologists should note, however, that irrespective of the mechanism(s) of effect, there are still numerous technical challenges to solve before AHSCT or other stem cell-based interventions can realise their full clinical impact. While advances can be made with well-regulated clinical research, the process will necessarily be iterative if excessive morbidity and mortality are to be avoided. . In summary, however, cells may be isolated from the patient (autologous) or donated by others (allogeneic) and the specific cell type must be considered. Haematopoietic stem cells are key to AHSCT but increasingly, it is appreciated that other cell populations have regenerative potential. These include mesenchymal stromal cells isolated from bone marrow or other sources, for example, adipose tissue. Mesenchymal stromal cells have many properties that are attractive for cell-based therapy 6 but, as yet, randomised, placebo-controlled trials in neurological diseases including MS have not demonstrated clinical benefit.
It is recognised that unscrupulous providers may target vulnerable patient populations marketing interventions that are unproven and potentially dangerous. This worldwide issue is proving difficult to regulate and requires ongoing collaboration between state regulators, patient advocacy groups, clinicians and scientists, [9] [10] [11] but it should be emphasised to patients that regulated clinical research rarely, if ever, requires participants to pay for inclusion.
Autologous hAemAtopoIetIc stem cell trAnsplAntAtIon
AHSCT is a well-established therapeutic option in haemato-oncology. Replacing the haematological system goes hand in hand with regenerating a 'new' immune system, explaining its potential in autoimmune disease. However, treatment-related toxicity has restricted its use to only a small proportion of patients with highly aggressive, treatment-refractory diseases, including those with systemic sclerosis and systemic lupus erythematosus. 12 The mechanism(s) by which AHSCT exerts clinical effects in MS is not entirely certain but probably involves immunomodulation in favour of regulatory cells with suppression of proinflammatory lymphocytes. 13 Such 're-setting' must be preceded by attempts essentially to 'remove' the patient's original immune system ('conditioning') before transplantation, and so AHSCT can be broken down into stages: stem cell collection, graft preparation and storage, conditioning regimen, and transplant delivery and engraftment (figure 1).
How to do it hAemopoIetIc stem cell collectIon, grAft prepArAtIon And storAge Before collection, patients for AHSCT require screening for herpes simplex virus, varicella zoster virus, HIV and the hepatitides. Although haematopoietic stem cells comprise only 0.01% of nucleated cells in the marrow, they can restore all blood lineages following myeloablation. 14 The key marker in clinical practice used to predict functional engraftment is the peripheral CD34-positive cell count, with a requirement for 2-3×10 6 CD34-positive cells/ kg body weight. 15 Until recently, autologous or allogeneic cells were isolated by bone marrow harvest involving multiple transcortical punctures of bone, usually posterior iliac crest, and aspiration of marrow under general anaesthesia. Increasingly however, clinicians use cytokine-mediated mobilisation of cells into peripheral blood using low-dose chemotherapy, granulocyte colony-stimulating factor and/or stem cell factor followed by apheresis. Unexpectedly, using granulocyte colony-stimulating factor alone may be associated with an MS flare, so it is frequently combined with corticosteroids or cyclophosphamide. 16 Umbilical cord blood is an alternative cell source; although the low CD34-positive cell dose previously restricted use of cord blood to children, there are now improving outcomes in adults. 17 Following collection, cells may be stored without manipulation or be T-cell depleted with the aim of further reducing autoreactivity following engraftment. 14 18 Although haematopoietic stem cells can be infused fresh, more commonly they are cryopreserved for storage.
conditioning regimen
Patients undergoing AHSCT are exposed to a conditioning regimen designed to either eradicate malignant cells or to eliminate autoreactive cells in autoimmune diseases. The conditioning regimen is classified as 'high', 'intermediate' or 'low' intensity according to the degree of myeloablation; this predicts to a large degree the procedure-associated risk and morbidity. 'High' intensity regimens may include total body irradiation and/or myeloablative chemotherapy, frequently combined with immune-depleting drugs such as antithymocyte globulin, alemtuzumab or rituximab to further suppress autoreactive cells. 18 These are associated with improved outcomes in preclinical studies but increased transplant-related mortality in patients. 19 20 'Low'-intensity regimens aim for lymphoablation only but may have limited long-term efficacy. In European studies, the most frequently employed regimen is 'BEAM'-an 'intermediate'-intensity regimen including carmustine, etoposide, cytarabine and melphalan, often followed by antithymocyte globulin. 16 
trAnsplAnt delIvery And engrAftment
The source of haematopoietic stem cells is infused intravenously following exposure to the conditioning regimen and functional engraftment is expected to occur in approximately 2 weeks. Longer term immunological changes include a sustained inversion of CD4/CD8 ratio 21 and a broader clonal diversity in T-cell receptor repertoire, potentially making patients susceptible to opportunistic infections such as Pneumocystis jirovecii pneumonia, 22 although many centres recommend routine prophylaxis only while the CD3 lymphocyte count is below 300×10 6 cells/L. Post-transplantation, patients need regular monitoring of full blood count including lymphocytes for at least 2 months to ensure sustained engraftment, and clinicians should maintain a high index of suspicion to consider rescreening for herpes simplex virus, varicella zoster virus and HIV if relevant symptoms emerge at any time after transplantation.
Ahsct for ms: whAt Are the rIsks?
The source and processing of cells for transplantation critically determine the likely safety of the approach and each has potential advantages and disadvantages. With respect to specific risks of transplantation, autologous therapies are not associated with risks of immunosuppression or graft-versus-host disease which may complicate allogeneic transplants; however, autologous cells may have inherent deficits associated with either MS or its comorbidities. 23 24 Additional risks include those associated with a bone marrow harvest performed under general anaesthetic or an MS flare after receiving a bone marrow mobilising agent. Furthermore, manipulation of cells ex vivo may be complicated by infection or cell transformation due to induction of genetic instability. Rarely, reactions to chemicals such as dimethyl sulfoxide used in cryopreservation may cause anaphylaxis.
Overall, however, the greatest risks are associated with myeloablative procedures due to neutropenic sepsis and haemorrhage in the context of thrombocytopaenia; these contribute disproportionately to the estimated 2%-3% risk of transplant-related mortality associated with AHSCT. 25 In general, patients with MS face similar regimen-related risks as patients undergoing transplantation for other indications but a number of complications occur either more frequently or more severely, including increased incidence of urinary tract infections, transient worsening of MS-related symptoms due to febrile neutropaenia or infection (pseudorelapse), reactivation of human herpes viruses following CD34 selected grafts or antithymocyte globulin treatment, as well as the additive effect on disability of neurotoxic conditioning regimens. 18 Late complications may also include development of secondary autoimmunity, which affects approximately 9% in all patients treated with autologous AHSCT for autoimmune disease. 26 Concomitant Rituximab infusion can be associated with serious infections including viral reactivation and progressive multifocal leucoencephalopathy, although rarely.
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Key points
► Autologous haematopoietic stem cell transplantation (AHSCT) is associated with risk of significant morbidity and mortality in patients with multiple sclerosis (MS), the more so when conducted in centres outside internationally agreed regulatory processes; it can be considered for aggressive relapsing and remitting MS but there is no clear benefit of AHSCT in progressive MS. ► Patients who pursue AHSCT on a direct-to-consumer basis should ensure that the centre conforms to internationally agreed standards. ► Due care must be given to travel arrangements and follow-up post-procedures, particularly for those who have received myeloablative conditioning regimens. ► Aside from AHSCT in carefully defined circumstances and settings, no form of stem cell 'treatment' for MS can be recommended outside the context of a properly regulated clinical trial; participants should not be expected to pay for inclusion.
key consIderAtIon for pAtIents consIderIng heAlth 'tourIsm' Given the significant risks of morbidity and mortality, AHSCT for patients with MS can, at present, be recommended only in the context of a properly regulated clinical study or trial. Patients must also consider the potential implications of travelling in the immediate period following myeloablative procedures, when they may be thrombocytopaenic or significantly immunosuppressed. Furthermore, AHSCT or involvement in unregulated experimental procedures is highly likely to disbar patients from future participation in clinical trials. Transplant centres around the world are subject to varying degrees of regulation but patients should be informed that there are internationally agreed standards. Centres conducting AHSCT should have accreditation with the International Society for Cellular Therapy and the European Society for Blood and Marrow Transplantation (EBMT) via the Joint Accreditation Committee (JACIE). Outcome data should be reported to EBMT or another transplant registry. Transplant centre clinicians also need to be aware of the specific needs and risks that patients with MS face; those centres more familiar with treating patients with MS tend to have better outcomes. 18 For patients determined to travel to access AHSCT offered commercially, we recommend they review the provider's reputation and safety record with care. We advise review of the EBMT/JACIE patient guidance 28 29 and our additional recommendations are:
1. The centre must have JACIE accreditation and outcome data must be reported to EBMT or another transplant registry. The experience of the centre in treating patients with MS should be noted. 2. Transplant centres must perform a rigorous pre-transplant assessment of the patient's suitability and fitness for the procedure and discuss any procedure-associated risks in the context of MS and additional co-morbidities. 3. The patient should check in advance whether the clinic is adequately prepared to handle emergencies such as a serious allergic reaction or cardiac arrest and enquire about contingency plans should complications occur. 4. Transplant centres must provide recommendations regarding post-procedure travel arrangements in advance of treatment and agree to issue a discharge summary to the regular care provider, including details of the conditioning regimen and cell infusion as well as any complications encountered. 5. The transplant centre must specify requirements for follow-up and monitoring together with information regarding potential risks of treatment in the immediate future and longer term.
For patients considering other stem cell 'treatments', we can recommend inclusion only in the context of a regulated clinical trial. Patients should be particularly cautious if required to pay for an intervention that is not approved by the relevant national regulatory authority.
conclusIons
Patients with MS experience understandable frustration with the slow progress in developing of novel and effective treatments, particularly for progressive disease. However, the urge to 'do something' can encourage people to consider unproven interventions of uncertain benefit despite their often-significant risk profile which may include death and worsening disability. Wherever possible, patients should be encouraged to participate in well-regulated, carefully conducted clinical trials and registry studies where adverse events are closely monitored and with available adequate clinical back-up (should there be complications) and good follow-up care. Ultimately, trials will establish whether AHSCT is effective and will inform improvements in both the procedure and patient selection. Patients who can consent to travel for the purpose of accessing direct-to-consumer treatments of uncertain benefit should be carefully advised of the potential risks, preferably in writing, and clinicians should take safeguarding measures where there are concerns regarding capacity for consent.
